Most people with ALS live 2 to 5 years after their first symptoms appear. The median survival from the point of diagnosis is about 20 months, though the gap between first symptoms and diagnosis typically adds several more months to the total timeline. These numbers represent the middle of a wide range, and several factors can shift an individual’s outlook significantly in either direction.
Survival From Diagnosis vs. Symptom Onset
There’s an important distinction between survival from diagnosis and survival from when symptoms first appear. ALS often takes months to diagnose because early symptoms like muscle twitching, weakness in one hand, or slurred speech can mimic other conditions. A large study published in Neurology found the median survival after diagnosis is about 20 months, which corresponds to roughly 2.5 years from symptom onset once you account for the diagnostic delay.
That 2.5-year median means half of people live longer and half live shorter. The full range stretches much wider. According to the ALS Association, about 20% of people live five years or more, around 10% live past ten years, and roughly 5% survive 20 years or longer. Stephen Hawking, diagnosed at 21 and surviving to 76, is the most famous example of this long tail, but he was genuinely exceptional.
Where ALS Starts Matters
ALS typically begins in one of two ways: in the limbs or in the muscles controlling speech and swallowing (called bulbar onset). This distinction is one of the strongest predictors of how the disease will progress.
Bulbar-onset ALS, which accounts for roughly a quarter of cases, tends to move faster. Life expectancy with bulbar onset may be two years or less. The reason isn’t simply that bulbar symptoms are more aggressive. People with bulbar onset tend to be older at diagnosis, are less likely to tolerate certain treatments, and face earlier respiratory complications. Once breathing is significantly affected, the monthly mortality rate for bulbar-onset patients is about twice that of limb-onset patients.
Limb-onset ALS, where weakness begins in an arm or leg, generally allows more time. These patients still face the same eventual trajectory, but the path to respiratory failure is typically longer, and they tend to respond better to breathing support.
Age at Diagnosis
Younger people diagnosed with ALS tend to live longer than those diagnosed later in life. ALS most commonly strikes between ages 55 and 75, and older age at onset is consistently linked with faster progression. People diagnosed in their 40s or earlier often fall into the group that survives well past the five-year mark, though this isn’t guaranteed. The reasons likely involve both the body’s general resilience at younger ages and the possibility that early-onset ALS may involve slower disease subtypes.
How ALS Causes Death
Respiratory failure is the primary cause of death in ALS. As the disease progresses, the muscles that control breathing, including the diaphragm and the muscles between the ribs, weaken. This doesn’t happen suddenly. It’s a gradual decline that typically begins with shortness of breath during exertion, then at rest, then during sleep. Many people first notice they’re waking up with headaches or feeling unrested, signs that carbon dioxide is building up overnight because their breathing muscles aren’t keeping up.
The timeline from when respiratory symptoms become noticeable to when breathing support is needed varies, but it’s often a matter of months rather than years.
How Breathing Support Changes the Timeline
Breathing support is the single most impactful intervention for extending life with ALS. Non-invasive ventilation, a mask worn primarily at night that helps push air into the lungs, both improves quality of life and extends survival. Most ALS centers introduce it early, often before a person feels they truly need it.
For people who choose more aggressive intervention, a tracheostomy with permanent mechanical ventilation can extend life substantially. A Danish study found tracheostomy patients lived an additional 3 to 5 years on ventilation. A Japanese study reported an average of 6.7 years of prolonged life with invasive ventilation. The tradeoff is significant: full-time ventilator dependence requires around-the-clock care, and by this stage most people have lost the ability to move, speak, and swallow. Some people find this quality of life acceptable, particularly with eye-tracking communication devices. Others do not. This is a deeply personal decision, and one that ideally gets discussed well before it becomes urgent.
What Medications Can Do
Riluzole, the first drug approved for ALS, works by reducing damage to motor neurons. The original clinical trials showed a modest benefit of 2 to 3 months. But real-world data paints a more encouraging picture. A review of eight studies found that patients taking riluzole had a median survival 6 to 19 months longer than those who didn’t. The gap between trial results and real-world outcomes likely reflects the fact that riluzole works best when started early and taken consistently over time, conditions that are easier to maintain outside the rigid structure of a clinical trial.
Riluzole doesn’t reverse symptoms or stop the disease. It slows progression modestly. Other approved treatments focus on managing specific symptoms like muscle stiffness, excess saliva, or emotional episodes, and multidisciplinary care teams that coordinate nutrition, physical therapy, and respiratory monitoring have been shown to improve both survival and quality of life beyond what any single drug offers.
Signs the Outlook May Be Better
Certain patterns are associated with slower progression. Limb onset (especially starting in a single leg), younger age at diagnosis, longer time between first symptoms and diagnosis (which itself suggests slower progression), and strong respiratory function at the time of diagnosis all point toward a better prognosis. People who maintain their weight and nutritional status also tend to do better, because the body’s caloric demands increase as weakened muscles work harder.
Survival statistics have also improved slightly over time. The Neurology study tracking patients from 1995 to 2018 found that median survival from diagnosis increased by about 10% over that period, rising from 18.6 months in earlier years to 20.1 months in the most recent period. That gain is modest but real, and likely reflects better multidisciplinary care, earlier use of breathing support, and improved nutritional management rather than any single breakthrough drug.